1-3 of 3
PierLuigi Zinzani
Close
Sort by
Journal Articles

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Annalisa Chiappella, Anna Dodero, Anna Guidetti, Filippo Bagnoli, MD, Vanessa Aragona, Anna Maria Barbui, MD, Stefania Bramanti, MD, Matteo Giovanni Carrabba, MD, Federica Sorà, MD, Pierluigi Zinzani, Prof, MD, Chiara Monfrini, Cristiana Carniti, Paolo Corradini
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-140054
Published: 2020
Journal Articles

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

Clinical Trials & Observations
Alessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, Emanuela Carlotti, Luca Arcaini, Michele Baccarani, Tiziano Barbui, Carlo Bernasconi, Giuseppe Dastoli, Giovanna Fuga, Enrica Gamba, Livio Gargantini, Valter Gattei, Francesco Lauria, Mario Lazzarino, Franco Mandelli, Enrica Morra, Alessandro Pulsoni, Michela Ribersani, Pier Luigi Rossi-Ferrini, Maurizio Rupolo, Sante Tura, Vittorina Zagonel, Francesco Zaja, PierLuigi Zinzani, Gigliola Reato, Robin Foa
Journal: Blood
Blood (2002) 99 (3): 856–862.
https://doi.org/10.1182/blood.V99.3.856
Published: 2002
Journal Articles

Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications

Francesco Lauria, Monica Bocchia, Giuseppe Marotta, Donatella Raspadori, PierLuigi Zinzani, Damiano Rondelli
Journal: Blood
Blood (1997) 89 (5): 1838–1839.
https://doi.org/10.1182/blood.V89.5.1838
Published: 1997